{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:08:18Z","timestamp":1783822098594,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40261-026-01571-x","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:00:22Z","timestamp":1780941622000},"page":"883-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling the Budget Impact of Disease-Modifying Therapies in Infantile-Onset Spinal Muscular Atrophy"],"prefix":"10.1007","volume":"46","author":[{"given":"Sumaya","family":"Abuloha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-7478","authenticated-orcid":false,"given":"Mikael","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"1571_CR1","unstructured":"NINDS. Spinal muscular atrophy. NIH. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/spinal-muscular-atrophy. Accessed 8 Dec 2023."},{"issue":"1","key":"1571_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1571_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1843277","volume":"8","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Kulas S, McGinnis E, Dabbous O, Jarecki J. Economic burden of spinal muscular atrophy: an analysis of claims data. J Mark Access Health Policy. 2020;8(1):1843277. https:\/\/doi.org\/10.1080\/20016689.2020.1843277.","journal-title":"J Mark Access Health Policy"},{"issue":"3","key":"1571_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.36469\/63185","volume":"6","author":"H Tan","year":"2019","unstructured":"Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J Health Econ Outcomes Res. 2019;6(3):185\u201395. https:\/\/doi.org\/10.36469\/63185.","journal-title":"J Health Econ Outcomes Res"},{"issue":"8","key":"1571_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/13696998.2016.1198355","volume":"19","author":"EP Armstrong","year":"2016","unstructured":"Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822\u20136. https:\/\/doi.org\/10.1080\/13696998.2016.1198355.","journal-title":"J Med Econ"},{"issue":"2","key":"1571_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s41669-018-0093-0","volume":"3","author":"J Cardenas","year":"2019","unstructured":"Cardenas J, Menier M, Heitzer MD, Sproule DM. High healthcarer resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the Kids\u2019 Inpatient Database (KID). PharmacoEconomics - Open. 2019;3(2):205\u201313. https:\/\/doi.org\/10.1007\/s41669-018-0093-0.","journal-title":"PharmacoEconomics - Open"},{"issue":"3","key":"1571_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijns7030033","volume":"7","author":"K Hale","year":"2021","unstructured":"Hale K, Ojodu J, Singh S. Landscape of spinal muscular atrophy newborn screening in the United States: 2018-2021. Int J Neonatal Screen. 2021;7(3):33. https:\/\/doi.org\/10.3390\/ijns7030033.","journal-title":"Int J Neonatal Screen"},{"key":"1571_CR8","unstructured":"US FDA. Spinraza. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf. Accessed 29 Feb 2024."},{"key":"1571_CR9","unstructured":"US FDA. Zolgensma. https:\/\/www.fda.gov\/media\/126109\/download?attachment. Accessed 29 Feb 2024."},{"key":"1571_CR10","unstructured":"US FDA. Evrysdi. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. Accessed 29 Feb 2024."},{"key":"1571_CR11","unstructured":"NCT02193074. A study to assess the efficacy and safety of nusinersen (ISIS 396443) in infants with spinal muscular atrophy (ENDEAR). https:\/\/clinicaltrials.gov\/study\/NCT02193074?cond=NCT02193074&rank=1. Accessed 29 Feb 2024."},{"key":"1571_CR12","unstructured":"NCT02122952. Gene transfer clinical trial for spinal muscular atrophy type 1. https:\/\/clinicaltrials.gov\/study\/NCT02122952?cond=NCT02122952&rank=1. Accessed 29 Feb 2024."},{"key":"1571_CR13","unstructured":"NCT02913482.\u00a0Investigate safety, tolerability, PK, PD and efficacy of risdiplam (RO7034067) in infants with type 1 spinal muscular atrophy (FIREFISH). https:\/\/clinicaltrials.gov\/study\/NCT02913482?cond=NCT02913482&rank=1. Accessed 29 Feb 2024."},{"issue":"18","key":"1571_CR14","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"HR Mendell","year":"2017","unstructured":"Mendell HR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"issue":"18","key":"1571_CR15","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1702752.","journal-title":"N Engl J Med"},{"issue":"12","key":"1571_CR16","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/s1474-4422(22)00339-8","volume":"21","author":"R Masson","year":"2022","unstructured":"Masson R, et al. Safety and efficacy of Risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110\u20139. https:\/\/doi.org\/10.1016\/s1474-4422(22)00339-8.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1571_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.18553\/jmcp.2019.25.12.1306","volume":"25","author":"CI Starner","year":"2019","unstructured":"Starner CI, Gleason PP. Spinal muscular atrophy therapies: ICER grounds the price to value conversation in facts. J Manag Care Spec Pharm. 2019;25(12):1306\u20138. https:\/\/doi.org\/10.18553\/jmcp.2019.25.12.1306.","journal-title":"J Manag Care Spec Pharm"},{"key":"1571_CR18","unstructured":"Why is Zolgensma so expensive? https:\/\/www.drugs.com\/medical-answers\/zolgensma-expensive-3552644\/#:~:text=Official%20answer&text=Zolgensma%20is%20a%20one%2Dtime,million%20for%20the%20single%20treatment. Accessed 1 Nov 2024."},{"key":"1571_CR19","unstructured":"Liu A. Roche's low-price Evrysdi will take 'meaningful' SMA share from Biogen's Spinraza: analyst. Fiercpharama. https:\/\/www.fiercepharma.com\/marketing\/roche-s-low-price-evrysdi-will-take-meaningful-sma-share-from-biogen-s-spinraza-analyst#:~:text=Roche%20priced%20Evrysdi%20based%20on,The%20reason?. Accessed 27 Jun 2024."},{"issue":"1","key":"1571_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/cer-2017-0068","volume":"7","author":"G Hampson","year":"2018","unstructured":"Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15\u201328. https:\/\/doi.org\/10.2217\/cer-2017-0068.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1571_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18553\/jmcp.2022.28.1.39","volume":"28","author":"J Ballreich","year":"2022","unstructured":"Ballreich J, Ezebilo I, Khalifa BA, Choe J, Anderson G. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs. J Manag Care Spec Pharm. 2022;28(1):39\u201347. https:\/\/doi.org\/10.18553\/jmcp.2022.28.1.39.","journal-title":"J Manag Care Spec Pharm"},{"key":"1571_CR22","unstructured":"Spinraza\u00ae and Zolgensma\u00ae for spinal muscular\u00a0atrophy: effectiveness and value.\u00a0Final Evidence Report. ICER; 2019."},{"issue":"1","key":"1571_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"issue":"1","key":"1571_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484. https:\/\/doi.org\/10.1080\/20016689.2019.1601484.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"1571_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9(1):1889841. https:\/\/doi.org\/10.1080\/20016689.2021.1889841.","journal-title":"J Mark Access Health Policy"},{"key":"1571_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, Ren S, Ellis AG, Chapman RH. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41. https:\/\/doi.org\/10.1186\/s12962-020-00234-8.","journal-title":"Cost Eff Resour Alloc"},{"issue":"12","key":"1571_CR27","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1007\/s00415-022-11319-0","volume":"269","author":"T Wang","year":"2022","unstructured":"Wang T, Scuffham P, Byrnes J, Downes M. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia. J Neurol. 2022;269(12):6544\u201354. https:\/\/doi.org\/10.1007\/s00415-022-11319-0.","journal-title":"J Neurol"},{"issue":"6","key":"1571_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jval.2020.09.021","volume":"24","author":"TF Broekhoff","year":"2021","unstructured":"Broekhoff TF, et al. Early cost-effectiveness of onasemnogene abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759\u201369. https:\/\/doi.org\/10.1016\/j.jval.2020.09.021.","journal-title":"Value Health"},{"issue":"1","key":"1571_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0022-510x(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372. https:\/\/doi.org\/10.1016\/s0022-510x(96)00284-5.","journal-title":"J Neurol Sci"},{"key":"1571_CR30","unstructured":"NCT02292537. A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later-onset spinal muscular atrophy (SMA) (CHERISH). https:\/\/clinicaltrials.gov\/study\/NCT02292537. Accessed 26 Jul 2024."},{"key":"1571_CR31","unstructured":"NCT02908685. A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in type 2 and 3 spinal muscular atrophy (SMA) participants (SUNFISH). https:\/\/clinicaltrials.gov\/study\/NCT02908685?cond=spinal%20muscular%20atrophy&limit=100&term=SUNFISH&rank=1#study-plan. Accessed 31 Oct 2024."},{"issue":"4","key":"1571_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/s1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393. https:\/\/doi.org\/10.1016\/s1474-4422(21)00001-6.","journal-title":"Lancet Neurol"},{"key":"1571_CR33","unstructured":"Belter L, Whitmire S, Welsh E, Schroth M. Cure SMA's 2023 state of SMA report. Cure SMA. https:\/\/www.curesma.org\/wp-content\/uploads\/2024\/06\/9042024_State-of-SMA_vWeb.pdf. Accessed 4 Sep 2024."},{"key":"1571_CR34","unstructured":"Martin J, Hamilton B, Osterman M. Births in the United States, 2023. NCHS Data Brief No. 507. CDC. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db507.htm. Accessed 4 Sep 2024."},{"issue":"31","key":"1571_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.15585\/mmwr.mm7331a1","volume":"73","author":"F Ahmad","year":"2024","unstructured":"Ahmad F, Cisewski J, Anderson R. Mortality in the United States: provisional data, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(31):677\u201381.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"1571_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027\u201349. https:\/\/doi.org\/10.1177\/0883073807305788.","journal-title":"J Child Neurol"},{"key":"1571_CR37","unstructured":"WebPlotdigitizer. https:\/\/apps.automeris.io\/wpd4\/. Accessed Aug 2024."},{"issue":"1","key":"1571_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"key":"1571_CR39","unstructured":"Zhou Y, Liu N, Lee JJ. IPDfromKM: reconstruct individual patient data (IPD) from Kaplan-Meier survival curve. https:\/\/www.trialdesign.org\/one-page-shell.html#IPDfromKM. Accessed Aug 2024."},{"issue":"5","key":"1571_CR40","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509\u201314. https:\/\/doi.org\/10.1542\/peds.2012-2278.","journal-title":"Pediatrics"},{"issue":"5","key":"1571_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/cer-2021-0216","volume":"11","author":"VA Ribero","year":"2022","unstructured":"Ribero VA, et al. How does risdiplam compare with other treatments for types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J Comp Eff Res. 2022;11(5):347\u201370. https:\/\/doi.org\/10.2217\/cer-2021-0216.","journal-title":"J Comp Eff Res"},{"key":"1571_CR42","unstructured":"CMS. DMEPOS fee schedule. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/dmepos\/dmepos-fee-schedule\/dme24-d. Accessed 26 Sep 2024."},{"key":"1571_CR43","unstructured":"Biogen. A guide to SPINRAZA reimbursement. https:\/\/www.spinrazahcp.com\/content\/dam\/commercial\/spinraza\/hcp\/en_us\/pdf\/spz-us-0134_reimbursement-guide.pdf. Accessed 7 Aug 2024."},{"key":"1571_CR44","unstructured":"Novartis. Zolgensma HCP coding and\u00a0billing guide. https:\/\/www.zolgensma-hcp.com\/pdf\/zolgensma-coding-and-billing-guide.pdf. Accessed 7 Aug 2024."},{"key":"1571_CR45","unstructured":"Genentech. Evrysdi spinal muscular atrophy (SMA) billing codes. https:\/\/www.genentech-access.com\/content\/dam\/gene\/accesssolutions\/pdfs\/coding\/Evrysdi-Billing-Coding-for-SMA.pdf. Accessed 7 Aug 2024."},{"key":"1571_CR46","unstructured":"US Department of Veterans Affairs. Office of Procurement, Acquisition and Logistics (OPAL). Pharmaceutical prices. https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp. Accessed 18 Sep 2024."},{"key":"1571_CR47","unstructured":"CMS. Physician fee schedule. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search. Accessed 7 Aug 2024."},{"key":"1571_CR48","unstructured":"CMS. Clinical laboratory fee schedule. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs\/files\/24clabq3. Accessed 7 Aug 2024."},{"key":"1571_CR49","unstructured":"FRED. Consumer price index for all urban consumers: all items in U.S. city average. https:\/\/fred.stlouisfed.org\/series\/CPIAUCSL#0. Accessed 5 Sep 2024."},{"issue":"10","key":"1571_CR50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"issue":"9","key":"1571_CR51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/wnl.0000000000000741","volume":"83","author":"RA Finkel","year":"2014","unstructured":"Finkel RA, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000000741.","journal-title":"Neurology"},{"key":"1571_CR52","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/j.jval.2019.04.1644","volume":"22","author":"D Malone","year":"2019","unstructured":"Malone D, et al. PRO10 use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: a United States payer budget impact analysis. Value Health. 2019;22:S336\u20137.","journal-title":"Value Health"},{"issue":"2","key":"1571_CR53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.18553\/jmcp.2018.18205","volume":"25","author":"MK Kuester","year":"2019","unstructured":"Kuester MK, Jackson EA, Runyan BM, Pezalla EJ, Nussbaum SR. The effect of a pediatric rare disease on subscriber retention rates for commercial health insurers in the United States. J Manag Care Spec Pharm. 2019;25(2):186\u201395. https:\/\/doi.org\/10.18553\/jmcp.2018.18205.","journal-title":"J Manag Care Spec Pharm"},{"key":"1571_CR54","unstructured":"US Department of Veterans Affairs. VA Federal Supply Schedule Service. https:\/\/www.fss.va.gov\/index.asp. [Accessed 16 Mar 2025."},{"issue":"12","key":"1571_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-025-06560-4","volume":"184","author":"AK Mittal","year":"2025","unstructured":"Mittal AK, et al. Economic evidence on the cost-effectiveness of newborn screening for spinal muscular atrophy: a systematic review. Eur J Pediatr. 2025;184(12):774. https:\/\/doi.org\/10.1007\/s00431-025-06560-4.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"1571_CR56","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","volume":"12","author":"D Weidlich","year":"2023","unstructured":"Weidlich D, Servais L, Kausar I, Howells R, Bischof M. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther. 2023;12(4):1205\u201320. https:\/\/doi.org\/10.1007\/s40120-023-00489-2.","journal-title":"Neurol Ther"},{"issue":"1","key":"1571_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10198-025-01806-2","volume":"27","author":"I Valentini","year":"2026","unstructured":"Valentini I, et al. Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the Survival motor neuron 2 gene in Italy. Eur J Health Econ. 2026;27(1):77\u201394. https:\/\/doi.org\/10.1007\/s10198-025-01806-2.","journal-title":"Eur J Health Econ"},{"key":"1571_CR58","unstructured":"Nationwide Children\u2019s Hospital Price Information. https:\/\/www.nationwidechildrens.org\/your-visit\/billing-and-insurance\/pay-my-bill\/price-information-list. Accessed 27 Sep 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01571-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T02:02:15Z","timestamp":1783821735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01571-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sumaya Abuloha, Amie Goodin, Tianze Jiao, Manuela Corti, and Mikael Svensson have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethics approval was not applicable for this study, as no human participants, identifiable patient data, or biological samples were involved. The analysis is based entirely on published aggregate data from clinical trials, observational registries, and publicly available administrative databases.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data sources that were used in the analyses are cited in the article and supplementary material. The model file is available upon request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: SA, MS; methodology: SA, MS; data acquisition: SA; formal analysis and investigation: SA; interpretation and implications: SA, MS, AG; writing (original draft preparation): SA; critical reviewing and editing: SA, MS, AG, TJ, MC; supervision: MS, AG. All authors read and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"This study was submitted previously to the graduate school at the University of Florida as a part of the student\/first author (Sumaya Abuloha) dissertation requirements for the PhD degree.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Publication"}}]}}